Palmitoyl Tripeptide-1 and Palmitoyl Pentapeptide-4 frequently appear together in formulations designed for firming, reducing the appearance of fine lines, and improving skin elasticity. The two peptides share a similar molecular design: one end consists of a lipophilic palmitoyl chain, while the other consists of a short peptide sequence composed of specific amino acids. The palmitoyl chain primarily alters the partitioning, stability, and release behavior of the short peptide within the formulation and the skin, whereas the GHK and KTTKS sequences determine the biological information that cells may receive.

The basis for combining Palmitoyl Tripeptide-1 and Palmitoyl Pentapeptide-4 lies in the fact that they correspond to different matrix-related peptide sequences and may participate in extracellular matrix regulation through different processes. GHK-related studies involve fibroblast responses, the status of basal epidermal cells, and cell–matrix adhesion, whereas KTTKS-related studies mainly involve type I procollagen feedback, fibroblast collagen production, and transforming growth factor beta-related regulation. Although the two peptides have different research focuses, both involve fibroblast responses and the regulation of collagen homeostasis, providing a theoretical basis for their combined use.

1 What Are Palmitoyl Tripeptide-1 and Palmitoyl Pentapeptide-4?

1.1 Both Ingredients Are Palmitoylated Short Peptides

Palmitoyl Tripeptide-1, free GHK tripeptide, and Copper Tripeptide-1 share the same GHK backbone but differ in their chemical forms:

Copper coordination in GHK-Cu affects its redox behavior, enzymatic regulation, and tissue-repair processes, whereas Pal-GHK is designed primarily to improve lipid compatibility and topical partitioning.

1.2 The Two Peptides Are Not Direct Raw Materials for Collagen Synthesis

Skin collagen is synthesized by fibroblasts through a series of processes, including gene transcription, protein translation, hydroxylation, triple-helix assembly, secretion, and extracellular processing. Topically applied GHK or KTTKS is not directly incorporated as a short fragment into intact collagen fibers.

The principal function of these two peptides is to provide biological signals:

① GHK is associated with research on collagen degradation, tissue repair, and extracellular matrix renewal;

② KTTKS is derived from a sequence associated with the carboxy-terminal propeptide of type I procollagen and may mimic feedback information generated during procollagen processing;

③ After receiving the relevant signals, fibroblasts may adjust the production of procollagen, collagen, and other extracellular matrix components.

Palmitoyl Tripeptide-1 and Palmitoyl Pentapeptide-4 are matrix-signaling peptides rather than nutritional ingredients that directly supplement collagen or serve as raw materials for collagen synthesis.

2 How Palmitoylation Alters the Skin Partitioning of Short Peptides

2.1 Conversion from Hydrophilic Short Peptides into Amphiphilic Lipopeptides

GHK and KTTKS contain multiple peptide bonds, amino groups, carboxyl groups, and hydrogen-bond-forming groups, giving them relatively strong overall hydrophilicity. The continuous phase of the stratum corneum is composed mainly of intercellular lipids such as ceramides, cholesterol, and free fatty acids. Hydrophilic short peptides therefore face partitioning limitations when moving from an aqueous formulation into this lipid region.

Palmitoylation involves attaching a 16-carbon palmitoyl chain to a short peptide. The resulting molecule contains both:

① A lipophilic long-chain hydrocarbon group;

② A hydrophilic or potentially charged peptide sequence.

This amphiphilic structure can improve the compatibility of the short peptide with stratum corneum lipids and alter its partitioning among the aqueous phase, oil phase, emulsified interfaces, and skin tissues. The palmitoyl chain helps improve conditions for local retention, while the GHK or KTTKS peptide headgroup preserves the corresponding sequence information.

2.2 Palmitoylation Improves Skin Retention but Does Not Eliminate the Stratum Corneum Barrier

Ex vivo skin experiments comparing KTTKS and Pal-KTTKS provide a direct evaluation of the effect of palmitoylation. The study used intact hairless mouse skin in Franz diffusion-cell experiments. After 24 hours, unmodified KTTKS was not detected in the stratum corneum, epidermis, or dermis. In contrast, 14.6% of the applied Pal-KTTKS dose was retained in the skin, with 8.3% in the stratum corneum, 5.6% in the epidermis, and 0.6% in the dermis. During the 48-hour experiment, neither peptide entered the receiver medium at quantifiable levels.[1]

These results indicate that palmitoylation substantially improved the skin retention and distribution of KTTKS across different skin layers. However, most Pal-KTTKS remained concentrated in the stratum corneum and epidermis, and only a small proportion entered the dermis. Palmitoylation changes the probability of skin partitioning but does not mean that the lipopeptide can cross intact skin in large quantities.

Because this experiment used hairless mouse skin under specific solvent conditions, its results cannot be directly equated with actual distribution in human skin. Nevertheless, it illustrates that a topically applied peptide must pass sequentially through the following processes before exerting an effect:

Remain stable within the formulation → Be released from the carrier or aggregate → Enter the lipid region of the stratum corneum → Establish local retention in the epidermis or dermis → Contact responsive cells while retaining an intact sequence.

2.3 Palmitoylation Also Alters Stability and Self-Assembly

The skin contains various proteases and peptidases, and unmodified short peptides are susceptible to hydrolysis. Experiments using hairless mouse skin extracts and homogenates showed that both KTTKS and Pal-KTTKS underwent degradation, although the relative stability of Pal-KTTKS was greater than that of KTTKS.[1]

The fatty-acid chain can also promote lipopeptide self-assembly. C16-KTTKS can form ribbon-like nanoscale aggregates in aqueous media and cell-culture medium. Studies using human dermal fibroblasts found that its collagen-production effect varied with concentration and became markedly stronger near the critical aggregation concentration, suggesting a relationship between the aggregation state of the lipopeptide and the cellular response.[2]

The changes produced by palmitoylation are therefore not limited to “improved penetration” and also include:

① Altering the dissolution and dispersion state of the lipopeptide within the formulation;

② Potentially changing the accessibility of the peptide chain to proteases and peptidases, thereby affecting its degradation rate;

③ Affecting the balance between free monomers and aggregates;

④ Altering the arrangement density of peptide sequences on the aggregate surface;

⑤ Controlling the release rate of the active peptide from emulsified systems or lipid carriers.

Different aggregation states affect the proportion of free lipopeptide, carrier release, diffusion, and local retention. Excessive aggregation may reduce the amount of free lipopeptide available for release and diffusion. Actual efficacy depends on the balance among stability, aggregation, release, and skin partitioning.

3 What Matrix-Related Information Do GHK and KTTKS Convey?

3.1 Design Basis of Pal-GHK: GHK-Related Cell–Matrix Regulation and Matrix Renewal

The GHK tripeptide sequence is present in the α2 chain of human type I collagen. Early studies proposed that short fragments containing GHK may be released during tissue injury or collagen degradation and may participate in the transmission of local repair signals. GHK-Cu, formed by complexing GHK with copper ions, can promote collagen synthesis in fibroblast cultures, and this increase is not caused by an increase in cell number.[3]

Free GHK also exhibits cellular regulatory effects independently of copper coordination. In normal human keratinocytes and skin-equivalent models, GHK treatment produced the following observations:

① Increased keratinocyte proliferation;

② Changes in the morphology of basal epidermal cells;

③ Increased expression of α6 and β1 integrins;

④ Increased numbers of cells positive for p63 and proliferating cell nuclear antigen.[4]

The α6 and β1 integrins participate in the adhesion of basal epidermal cells to the basement membrane and the surrounding extracellular matrix. These results indicate that the GHK sequence is associated not only with dermal fibroblasts and collagen production but may also regulate the adhesion and proliferation status of basal epidermal cells.

Pal-GHK contains a palmitoyl chain attached to GHK. Its skincare activity consists of two components:

The palmitoyl chain improves formulation compatibility and skin partitioning + The GHK sequence regulates basal keratinocytes, fibroblasts, and extracellular matrix renewal.

Published research on Pal-GHK is composed primarily of studies on GHK sequence activity and studies on Pal-GHK formulation delivery.

3.2 Pal-KTTKS: Mimicking Type I Procollagen-Related Feedback Information

Type I collagen is initially synthesized in the form of type I procollagen. Procollagen molecules contain amino-terminal and carboxy-terminal propeptides. After secretion into the extracellular space, these propeptides are removed by the corresponding enzymes, after which the collagen molecules assemble into fibrils and fibers.

KTTKS is a pentapeptide sequence associated with the carboxy-terminal propeptide of type I procollagen. Screening studies of type I procollagen fragments found that KTTKS increased the production of type I collagen, type III collagen, and fibronectin in fibroblasts without causing a generalized increase in the synthesis of all proteins.[5]

This result supports the procollagen feedback model:

Related peptide fragments are generated during procollagen processing or matrix renewal → Fibroblasts sense that collagen structures are undergoing renewal → The production of procollagen and other matrix components is adjusted.

Pal-KTTKS is a lipopeptide formed by attaching a palmitoyl chain to KTTKS. Studies using human dermal fibroblasts showed that C16-KTTKS increased the amount of collagen deposited by the cells in a concentration-dependent manner. Within the concentration range used in the study, the 0.008% C16-KTTKS group produced more total collagen than the basal-medium group and the control-stimulation group.[2]

This finding indicates that dermal fibroblasts are capable of responding to Pal-KTTKS. Whether a topical formulation produces a corresponding effect also depends on the amount of Pal-KTTKS released from the carrier, the integrity of the peptide chain, and the actual concentration reaching the dermis. Ex vivo skin experiments detected a small amount of Pal-KTTKS retained in the dermis, providing the possibility of contact with dermal cells, although most of the applied dose remained in the stratum corneum and epidermis.[1]

3.3 How Is KTTKS Related to TGF-β and Smad Proteins?

Transforming growth factor beta（TGF-β）is an important cytokine involved in regulating fibroblasts, collagen synthesis, and extracellular matrix homeostasis.

In the canonical TGF-β signaling pathway:

TGF-β binds to the type II receptor

→ The type II receptor recruits and activates the type I receptor

→ The type I receptor phosphorylates Smad2 and Smad3

→ Smad2/3 forms a complex with Smad4

→ The complex enters the nucleus

→ The transcription of collagen and other target genes is regulated.

Smad proteins are also regulated by inhibitory Smads, protein-degradation systems, and other signaling pathways. Consequently, cellular responses to TGF-β vary with cell type, concentration, and treatment duration.[6]

A study using rat Achilles tendon cells found that KTTKS treatment produced the following changes:

① Increased type I collagen protein expression;

② Increased α1（I）procollagen messenger RNA（mRNA）expression;

③ Increased TGF-β mRNA expression;

④ A dose-dependent increase in TGF-β concentration in the culture medium;

⑤ A reduced degradation rate of existing α1（I）procollagen mRNA.[7]

These findings indicate that KTTKS regulates type I collagen at least at two levels:

Existing studies have directly measured KTTKS-induced changes in TGF-β and procollagen mRNA stability but have not demonstrated direct binding between Pal-KTTKS and Smad proteins. Smad2/3 is located downstream of the TGF-β receptor and transmits receptor signals to the nucleus.

The relationship between Pal-KTTKS and Smad may therefore be expressed as follows:

KTTKS sequence-related signaling

→ Changes in TGF-β expression or release

→ Possible involvement of Smad2/3 downstream of the TGF-β receptor

→ Adjustment of collagen-related gene expression.

The regulation of collagen by Pal-KTTKS is also not limited to the TGF-β/Smad pathway. Procollagen mRNA stability, lipopeptide self-assembly, peptide-sequence presentation, and the cellular state itself may all contribute to the final response.

4 Why Do the Two Peptides Have a Basis for Combination?

4.1 The Same Lipidation Strategy Addresses Shared Delivery Challenges

Both Pal-GHK and Pal-KTTKS employ a “palmitoyl chain + signaling-peptide sequence” structure. They face several common challenges:

① Free short peptides are relatively hydrophilic;

② Stratum corneum lipids restrict peptide partitioning;

③ Peptide chains may be degraded by proteases in the skin;

④ Lipopeptides may form aggregates of different sizes within formulations;

⑤ Only intact peptides released from the carrier can achieve effective cellular exposure.

Their similar lipidated structures allow the two peptides to use comparable emulsification, solubilization, and lipid-carrier designs. However, they may still differ in solubility, aggregation concentration, and release rate. Each peptide must therefore be evaluated separately within the formulation, rather than assuming that they have identical delivery efficiency solely because they share a palmitoyl structure.

4.2 Different Sequence Information Broadens the Scope of Matrix Regulation

The main difference between the two peptides lies in their peptide headgroups:

Based on existing studies of GHK, GHK-Cu, KTTKS, and Pal-KTTKS, Pal-GHK and Pal-KTTKS may cover different aspects of matrix regulation, providing a theoretical basis for their combined use to broaden the scope of matrix regulation.

4.3 The Two Signals Converge at the Levels of Fibroblast Responses and Collagen Homeostasis

Although GHK and KTTKS differ in sequence origin and research focus, their downstream outcomes both involve fibroblasts, collagen, and extracellular matrix renewal.

This convergence may produce two possible situations:

① Complementary effects

Studies associated with the GHK and KTTKS sequences involve basal-cell adhesion, fibroblast responses, procollagen production, and matrix deposition, allowing the combination design to cover multiple related processes.

② Overlapping effects

The two peptides may both depend on the synthetic capacity of fibroblasts or on similar matrix-regulatory processes. When the cellular response approaches saturation, adding the other peptide may not produce a proportional additional increase.

The value of the combination therefore depends not only on whether the peptides contain different sequences but also on their effective doses, duration of action, local concentrations, and the extent to which their downstream pathways overlap.

5 Does Mechanistic Complementarity Equal Synergistic Enhancement?

Existing published original studies separately support the effects of GHK, GHK-Cu, KTTKS, and Pal-KTTKS in specific cellular or tissue models. However, complete controlled combination studies specifically evaluating Pal-GHK together with Pal-KTTKS remain limited. Therefore, whether a combination with mechanistic complementarity and a broader scope of matrix regulation produces synergistic enhancement must still be determined through experimental evaluation of the final combined formulation.

6 What Factors Determine the Final Skincare Effects?

6.1 The Addition Level of a Commercial Ingredient Is Not Equal to the Pure-Peptide Concentration

Peptide ingredients are generally supplied in the form of water, glycerol, solvents, solubilizers, preservative systems, or multi-peptide solutions. Adding a certain proportion of a commercial ingredient to a formulation does not mean that the final product contains the same proportion of pure peptide.

The actual effective dose involves several consecutive stages:

Commercial ingredient addition level

→ Pure-peptide content in the commercial ingredient

→ Theoretical peptide concentration in the final formulation

→ Concentration of intact peptide remaining after storage

→ Concentration of peptide released from the carrier

→ Local concentration entering the effective skin region.

An ingredient list can indicate only that the relevant ingredient has been used in the product. It cannot independently reveal the active-peptide concentration or actual skin exposure.

6.2 The Carrier Must Balance Stability, Release, and Skin Partitioning

If the interaction between the lipopeptide and the carrier is too weak, precipitation, uncontrolled aggregation, or degradation may occur. If binding to the oil phase, micelles, or aggregates is too strong, the proportion released from the formulation may be reduced.

A 2025 study of Pal-GHK formulations compared ethosomes, polyoxyethylene–polyoxypropylene block-copolymer gels, lecithin organogels, and composite semisolid systems. Different carriers had different effects on the solubilization, spreading, occlusivity, and release behavior of Pal-GHK, demonstrating that Pal-GHK delivery performance is determined by the composition of the complete formulation.[8]

Factors affecting the delivery of palmitoylated peptides include:

① Formulation pH and ionic strength;

② Oil-phase and emulsifier composition;

③ Polyols, alcohols, and surfactants;

④ The size and stability of lipopeptide aggregates;

⑤ The rate of peptide-chain degradation;

⑥ The residence time of the product on the skin.

The objective of formulation design is to maintain suitable lipopeptide stability while allowing the peptide to be released from the carrier and partition into the relevant skin region.

6.3 The Final Product Requires Independent Efficacy Validation

Pal-KTTKS has been evaluated in certain human formulation studies. One 12-week, double-blind, placebo-controlled, randomized split-face study involving 93 women compared a basic moisturizing formulation with the same formulation containing 3 ppm Pal-KTTKS. The side treated with Pal-KTTKS showed improvements in fine lines and wrinkles according to image analysis and expert assessment.[9]

This study supports improvements in human skin appearance produced by Pal-KTTKS at a specific concentration and within a specific formulation. However, it cannot directly represent the effects of other carriers, other concentrations, or combinations with Pal-GHK. For products containing both peptides, valuable forms of validation include:

① The actual concentrations of the two pure peptides in the final formulation;

② Peptide integrity during storage;

③ Release of the lipopeptides from the formulation and their distribution within the skin;

④ Controlled testing against the same base formulation without peptides;

⑤ Direct comparison of the two peptides used individually and in combination.

7 Classification and Research Applications of Representative Chemicals Related to the Skin Delivery, Matrix Signaling, and Collagen Regulation of Palmitoyl Tripeptide-1 and Palmitoyl Pentapeptide-4

Table 1. Products Related to Core Active Peptides, Sequence Components, and Copper Coordination Research

Table 2. Products Related to Solid-Phase Peptide Synthesis, Peptide-Bond Coupling, and Palmitoylation

Table 3. Products Related to Signaling Pathways, Collagen Matrices, and Extracellular Matrix Evaluation

Table 4. Products Related to Lipid Carriers, Model Membranes, and Skin Partitioning Research

Note: The products listed above are representative Aladdin products related to scientific research and formulation studies. Additional product specifications, grades, and certificate of analysis (COA) information can be searched on the Aladdin official website using the product name, CAS number, or catalog number.

References

[1] Choi YL, Park EJ, Kim E, Na DH, Shin YH. Dermal Stability and In Vitro Skin Permeation of Collagen Pentapeptides (KTTKS and Palmitoyl-KTTKS). Biomolecules & Therapeutics, 2014, 22(4): 321–327. doi:10.4062/biomolther.2014.053.

[2] Jones RR, Castelletto V, Connon CJ, Hamley IW. Collagen Stimulating Effect of Peptide Amphiphile C16-KTTKS on Human Fibroblasts. Molecular Pharmaceutics, 2013, 10(3): 1063–1069. doi:10.1021/mp300549d.

[3] Maquart FX, Pickart L, Laurent M, Gillery P, Monboisse JC, Borel JP. Stimulation of Collagen Synthesis in Fibroblast Cultures by the Tripeptide-Copper Complex Glycyl-L-Histidyl-L-Lysine-Cu²⁺. FEBS Letters, 1988, 238(2): 343–346. doi:10.1016/0014-5793(88)80509-X.

[4] Choi HR, Kang YA, Ryoo SJ, Shin JW, Na JI, Huh CH, Park KC. Stem Cell Recovering Effect of Copper-Free GHK in Skin. Journal of Peptide Science, 2012, 18(11): 685–690. doi:10.1002/psc.2455.

[5] Katayama K, Armendariz-Borunda J, Raghow R, Kang AH, Seyer JM. A Pentapeptide from Type I Procollagen Promotes Extracellular Matrix Production. Journal of Biological Chemistry, 1993, 268(14): 9941–9944. doi:10.1016/S0021-9258(18)82153-6.

[6] Hata A, Chen YG. TGF-β Signaling from Receptors to Smads. Cold Spring Harbor Perspectives in Biology, 2016, 8(9): a022061. doi:10.1101/cshperspect.a022061.

[7] Tsai WC, Hsu CC, Chung CY, Lin MS, Li SL, Pang JHS. The Pentapeptide KTTKS Promoting the Expressions of Type I Collagen and Transforming Growth Factor-β of Tendon Cells. Journal of Orthopaedic Research, 2007, 25(12): 1629–1634. doi:10.1002/jor.20455.

[8] Dzyhovskyi V, Santamaria F, Marzola E, Montesi L, Donelli I, Manfredini S, Guerrini R, Esposito E. Production and Characterization of Semi-Solid Formulations for the Delivery of the Cosmetic Peptide Palmitoyl-GHK. Cosmetics, 2025, 12(2): 50. doi:10.3390/cosmetics12020050.

[9] Robinson LR, Fitzgerald NC, Doughty DG, Dawes NC, Berge CA, Bissett DL. Topical Palmitoyl Pentapeptide Provides Improvement in Photoaged Human Facial Skin. International Journal of Cosmetic Science, 2005, 27(3): 155–160. doi:10.1111/j.1467-2494.2005.00261.x.

For more related articles, see below:

Analysis of Hydrolyzed Pearl as a Cosmetic Raw Material: Preparation Process, Active Components, and Skincare Formulation Applications

The Dual-Targeted Skin-Brightening Mechanism of 4-MSK: Inhibiting Melanin Production and Reducing Epidermal Pigment Retention

Antioxidant Mechanisms, Stability, and Delivery Strategies of Resveratrol in Skincare Research

Antioxidant Mechanisms of Ferulic Acid in Skincare, Vitamin C/E Synergy, and Stable Delivery Applications

Tocopherols in the Vitamin E Family: How They Block the Chain Reaction of Lipid Peroxidation in Skin Lipids

The Skin Anti-Aging Mechanisms of α-Lipoic Acid: ALA/DHLA Redox Cycling, the Antioxidant Network, and Regulation of Collagen AGE Formation

Mechanistic Analysis of Topical Glutathione in Skincare: Cellular Redox Regulation, Skin Delivery Challenges, and SLN-Based Delivery Strategies

Mechanism of Kojic Acid in Reducing Hyperpigmentation: From Tyrosinase Inhibition to Melanin Production Regulation

Beneath the Skin: Protein- and Peptide-Based Actives in Skincare and Aesthetic Medicine

Understanding Ceramides from the Perspective of the Stratum Corneum Lipid Barrier: Moisturizing and Barrier-Repair Mechanisms, Ingredient Selection, and Formulation Research Considerations

Hyaluronidase: Unlocking a “Magic Enzyme” in Biomedicine

Hyaluronan

Recombinant Humanized Type III Collagen: Structural Basis, Manufacturing Technologies, and Dermatological Applications

Trehalose: Physicochemical Characteristics, Manufacturing Processes, and Application Guidelines

Compounds found in Green Tea

Sources, Biological Functions, Isolation/Characterization, and Emerging Applications of Exosomes

Applicability Comparison of Vitronectin, Laminin and Fibronectin in Cell Culture Coating Systems

Cosmetic Peptides

Resveratrol

Ferulic Acid: Structural Features, Preparation Routes, and Key Points for Research Applications

Role of Sphingolipid Metabolic Remodeling in Apoptotic and Inflammatory Signaling

Cosmetic Grade Explained

How to decipher the whitening code?

Niacin (Vitamin B3): Structural Features, Metabolic Roles, and Application Landscape

The "Six Key Checkpoints" of Skin Lightening

Tyrosinase: a key regulatory enzyme in melanin synthesis and its biological and applied significance

Glutathione (GSH) Quantification: Method Systems, Experimental Workflows, and Key Quality-Control Considerations

Glutathione Reductase: A Flavin-Dependent Reductive System Maintaining GSH/GSSG Homeostasis, with Assays and Applications

What is Glutathione？

What Is Glutathione Agarose?

Enzymatic Hydroxylation Mechanism of Salicylate Conversion to Catechol